A股異動|悦康藥業升超7% 複方銀杏葉片全國多中心III期臨牀研究達到主要終點
悦康藥業(688658.SH)一度升近13%,股價刷新近四個月新高,現升7.68%報19.06元,總市值85.77億元。悦康藥業昨公吿,公司產品複方銀杏葉片關於治療輕、中度血管性痴呆(瘀阻腦絡證)的全國多中心III期臨牀研究達到主要終點。復銀片在主要療效指標(阿爾茨海默病評定量表認知部分(ADAS-Cog)評分與基線評分比較差值的組間差異)展示出優效性,安全性特徵良好,未報吿新的安全性警示。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.